US · Healthcare · Diagnostics & Research
Analysts rate Myriad Genetics Inc a hold (1 buy, 6 hold, 2 sell out of 9) with an average price target of $4.49.
| Fund | Stake |
|---|---|
| BlackRock Inc | 11.39% |
| Millennium Management LLC | 6.93% |
| Vestal Point Capital LP | 6.00% |
| State Street Corp | 5.21% |
| D. E. Shaw & Co LP | 4.79% |
| Vanguard Capital Management, LLC | 4.27% |
| Acadian Asset Management LLC | 3.27% |
| Vanguard Portfolio Management, LLC | 3.22% |
| Document | Date |
|---|---|
| Material agreement · Q4 2026 HEADLINE NUMBERS • Myriad Genetics agreed to sell its prenatal health business to Laboratory Corporation of America for $210 million in cash, plus th | 2026-10-20 |
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Myriad Genetics entered into a separation agreement with former Chief Commercial Officer Brian Donnelly on October 6, 2026. • Don | 2026-10-09 |
| Board / officer change · Q3 2026 BUSINESS & SEGMENT HIGHLIGHTS • Myriad Genetics announced a change in its commercial leadership. • Brian Donnelly no longer serves as Chief Commerci | 2026-09-16 |
| Quarterly report · Q2 2026 HEADLINE NUMBERS • Second-quarter 2026 revenue was $190.7 million, down from $213.1 million in the second quarter of 2025. • Six-month revenue was $ | 2026-07-31 |
| Results announced · Q3 2026 HEADLINE NUMBERS • Q2 2026 revenue was $190.7 million, down 11% year-over-year from $213.1 million. • Test volume was 379,000, down 1% year-over-yea | 2026-07-30 |
| Quarterly report · Q1 2026 HEADLINE NUMBERS • First-quarter 2026 revenue was $200.4 million, up from $195.9 million in the first quarter of 2025. • Gross profit was $137.6 mil | 2026-05-06 |
| Proxy statement · Q4 2025 CEO TOTAL COMPENSATION • The provided proxy excerpt does not include the Summary Compensation Table figures for CEO Samraat S. Raha, so his exact 202 | 2026-04-14 |
| Annual report FY2025 HEADLINE NUMBERS • Fiscal year ended December 31, 2025. • Common stock outstanding as of February 19, 2026: 93,508,165 shares. • Aggregate market v | 2026-02-24 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Myriad Genetics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.